Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Avadel Pharmaceuticals Plc's Business Segments
Avadel Pharmaceuticals Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 77
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2025
- Reportable100%
Revenue by Reportable Segment - Q3 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 77 | 100% |
Description of Avadel Pharmaceuticals Plc
Avadel Pharmaceuticals Plc is a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing innovative pharmaceutical products. The company is headquartered in Dublin, Ireland, and operates globally.
Avadel Pharmaceuticals specializes in the development of drugs for central nervous system (CNS) disorders, including sleep disorders, attention deficit hyperactivity disorder (ADHD), and epilepsy. The company's mission is to improve the lives of patients by developing novel treatments that address unmet medical needs.
The sleep disorder franchise is one of Avadel's key areas of focus. The company has developed a unique drug delivery technology called Micropump®, which allows for the controlled release of medications over an extended period of time. This technology is used in their flagship product, FT218, which is a once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
FT218 has shown promising results in clinical trials, demonstrating significant improvement in the symptoms of narcolepsy. Avadel has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218 and is currently awaiting regulatory approval.
In addition to their sleep disorder franchise, Avadel Pharmaceuticals also has a portfolio of other products. They have developed a range of methylphenidate-based products for ADHD under the brand name Bloxit™. These products provide once-daily dosing convenience and have been well-received in the market.
Avadel Pharmaceuticals is committed to expanding its product portfolio through both internal development and strategic collaborations. They actively seek opportunities to license, acquire, or co-develop specialty pharmaceutical products that align with their therapeutic areas of focus.
In terms of the company's financials, Avadel Pharmaceuticals has been steadily growing its revenue over the past few years. They generate revenue through the sale of their products, as well as royalties and milestone payments from their collaborations. The company has a diverse customer base, including wholesalers, specialty pharmacies, managed care organizations, and government agencies.
Avadel Pharmaceuticals has a dedicated team of scientists, researchers, and industry professionals who are passionate about advancing healthcare and improving patient outcomes. They have a strong commitment to research and development and continuously invest in innovation and clinical trials to bring new treatments to market.
Overall, Avadel Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing novel treatments for CNS disorders. With a pipeline of innovative products and a commitment to improving patient lives, the company is well-positioned for future success in the pharmaceutical industry.
Avadel Pharmaceuticals specializes in the development of drugs for central nervous system (CNS) disorders, including sleep disorders, attention deficit hyperactivity disorder (ADHD), and epilepsy. The company's mission is to improve the lives of patients by developing novel treatments that address unmet medical needs.
The sleep disorder franchise is one of Avadel's key areas of focus. The company has developed a unique drug delivery technology called Micropump®, which allows for the controlled release of medications over an extended period of time. This technology is used in their flagship product, FT218, which is a once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
FT218 has shown promising results in clinical trials, demonstrating significant improvement in the symptoms of narcolepsy. Avadel has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218 and is currently awaiting regulatory approval.
In addition to their sleep disorder franchise, Avadel Pharmaceuticals also has a portfolio of other products. They have developed a range of methylphenidate-based products for ADHD under the brand name Bloxit™. These products provide once-daily dosing convenience and have been well-received in the market.
Avadel Pharmaceuticals is committed to expanding its product portfolio through both internal development and strategic collaborations. They actively seek opportunities to license, acquire, or co-develop specialty pharmaceutical products that align with their therapeutic areas of focus.
In terms of the company's financials, Avadel Pharmaceuticals has been steadily growing its revenue over the past few years. They generate revenue through the sale of their products, as well as royalties and milestone payments from their collaborations. The company has a diverse customer base, including wholesalers, specialty pharmacies, managed care organizations, and government agencies.
Avadel Pharmaceuticals has a dedicated team of scientists, researchers, and industry professionals who are passionate about advancing healthcare and improving patient outcomes. They have a strong commitment to research and development and continuously invest in innovation and clinical trials to bring new treatments to market.
Overall, Avadel Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing novel treatments for CNS disorders. With a pipeline of innovative products and a commitment to improving patient lives, the company is well-positioned for future success in the pharmaceutical industry.
Avadel Pharmaceuticals Plc is a specialty pharmaceutical company that specializes in developing and commercializing products in the field of central nervous system disorders, specifically focusing on sleep disorders as well as other therapeutic areas. The company aims to address significant unmet medical needs with innovative formulations and delivery systems.
Segments
1. Pharmaceuticals:
Avadel operates primarily within the pharmaceutical segment, focusing on innovative drug formulations that can improve the treatment landscape for patients with sleep disorders and other conditions.
2. Development Services:
This segment includes the collaboration with other pharmaceutical companies for the development of new drug formulations and technologies.
3. Commercial Operations:
Avadel has built a presence in commercial operations to facilitate the distribution and marketing of its products. This includes sales teams working directly with healthcare providers, pharmacists, and hospitals to ensure availability and effective marketing of their pharmaceutical products.
Products
1. Synamel (formerly known as FT218):
Synamel is a novel formulation of sodium oxybate designed for the treatment of narcolepsy. This product leverages a proprietary delivery system to enhance the pharmacokinetics of the active ingredient, aiming to improve patient compliance and outcomes.
2. Other Products in Development:
Avadel has several other investigational compounds in various phases of development targeting sleep disorders, particularly focusing on improving the quality and duration of sleep for patients affected by conditions like insomnia and narcolepsy.
Services
1. Development and Formulation Services:
Avadel provides expertise in developing drug formulations that can be utilized in various therapeutic areas. This includes designing delivery systems that optimize drug absorption and therapeutic efficacy.
2. Regulatory Support:
Avadel offers regulatory support to ensure that products meet the necessary standards for market approval. This includes navigating the complexities of FDA submissions and other regulatory requirements.
3. Clinical Trial Management:
The company engages in managing the clinical trial process for their products to ensure that they meet the rigorous standards set forth for safety and efficacy. This includes recruiting sites, managing data, and ensuring compliance with regulatory bodies.
4. Commercialization Support:
Beyond product development, Avadel also focuses on commercialization strategies to bring their products to market successfully. This includes marketing, sales training, and distribution strategies aimed at healthcare professionals and patients.
5. Patient Education and Support Programs:
Avadel recognizes the importance of patient adherence to treatment and offers education and support programs to help patients understand their medications and the importance of adherence to prescribed therapy.
Avadel Pharmaceuticals Plc continues to innovate in the pharmaceutical landscape by focusing on unique drug formulations, conducting extensive research and development, and providing comprehensive support across various segments of the pharmaceuticals market.
Segments
1. Pharmaceuticals:
Avadel operates primarily within the pharmaceutical segment, focusing on innovative drug formulations that can improve the treatment landscape for patients with sleep disorders and other conditions.
2. Development Services:
This segment includes the collaboration with other pharmaceutical companies for the development of new drug formulations and technologies.
3. Commercial Operations:
Avadel has built a presence in commercial operations to facilitate the distribution and marketing of its products. This includes sales teams working directly with healthcare providers, pharmacists, and hospitals to ensure availability and effective marketing of their pharmaceutical products.
Products
1. Synamel (formerly known as FT218):
Synamel is a novel formulation of sodium oxybate designed for the treatment of narcolepsy. This product leverages a proprietary delivery system to enhance the pharmacokinetics of the active ingredient, aiming to improve patient compliance and outcomes.
2. Other Products in Development:
Avadel has several other investigational compounds in various phases of development targeting sleep disorders, particularly focusing on improving the quality and duration of sleep for patients affected by conditions like insomnia and narcolepsy.
Services
1. Development and Formulation Services:
Avadel provides expertise in developing drug formulations that can be utilized in various therapeutic areas. This includes designing delivery systems that optimize drug absorption and therapeutic efficacy.
2. Regulatory Support:
Avadel offers regulatory support to ensure that products meet the necessary standards for market approval. This includes navigating the complexities of FDA submissions and other regulatory requirements.
3. Clinical Trial Management:
The company engages in managing the clinical trial process for their products to ensure that they meet the rigorous standards set forth for safety and efficacy. This includes recruiting sites, managing data, and ensuring compliance with regulatory bodies.
4. Commercialization Support:
Beyond product development, Avadel also focuses on commercialization strategies to bring their products to market successfully. This includes marketing, sales training, and distribution strategies aimed at healthcare professionals and patients.
5. Patient Education and Support Programs:
Avadel recognizes the importance of patient adherence to treatment and offers education and support programs to help patients understand their medications and the importance of adherence to prescribed therapy.
Avadel Pharmaceuticals Plc continues to innovate in the pharmaceutical landscape by focusing on unique drug formulations, conducting extensive research and development, and providing comprehensive support across various segments of the pharmaceuticals market.